[Federal Register: March 21, 2008 (Volume 73, Number 56)]
[Rules and Regulations]
[Page 15060-15061]
[DOCID:fr21mr08-4]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2008-0072; Airspace Docket No. 08-ASO-03]

Establishment of Class E Airspace; Lady Lake, FL

AGENCY: Federal Aviation Administration WAA), DOT.

ACTION: Direct final rule, request for comments.

-----------------------------------------------------------------------

SUMMARY: This action establishes Class E Airspace at Lady Lake, FL to
support a new Area Navigation (RNAV) Global Positioning System (GPS)
Special Instrument Approach Procedure (IAP) that has been developed for
medical flight operations into the Village of Homewood Lady Lake
Hospital. This action enhances the safety and management of Instrument
Flight Rule (IFR) operations by providing that required controlled
airspace for this approach around Lady Lake, FL.

DATES: Effective 0901 UTC, June 05, 2008. The Director of the Federal
Register approves this incorporation by reference action under title 1,
Code of Federal Regulations, part 51, subject to the annual revision of
FAA Order 7400.9 and publication of conforming amendments. Comments for
inclusion in the Rules Docket must be received on or before May 5,
2008.

ADDRESSES: Send comments on this rule to: U.S. Department of
Transportation, Docket Management, West Building Ground Floor, Room
W12-140, 1200 New Jersey Ave., SE., Washington, DC 20590-0001;
Telephone: 1-800-647-5527; Fax:<PHONE_NUMBER>. You must identify the
Docket Number FAA-2008-0072; Airspace Docket No. 08-ASO-03, at the
beginning of your comments. You may also submit and review received
comments through the Internet at http://www.regulations.gov.
    You may review the public docket containing the rule, any comments
received, and any final disposition in person in the Dockets Office
(see ADDRESSES section for address and phone number) between 9 a.m. and
5 p.m., Monday through Friday, except Federal Holidays. An informal
docket may also be examined during normal business hours at the office
of the Eastern Service Center, Federal Aviation Administration, Room
210, 1701 Columbia Avenue, College Park, Georgia 30337.

FOR FURTHER INFORMATION CONTACT: Melinda Giddens, System Support Group,
Eastern Service Center, Federal Aviation Administration, P.O. Box
20636, Atlanta, Georgia 30320; telephone<PHONE_NUMBER>; fax (404) 305-
5572.

SUPPLEMENTARY INFORMATION:

The Direct Final Rule Procedure

    The FAA anticipates that this regulation will not result in adverse
or negative comments, and, therefore, issues it as a direct final rule.
The FAA has determined that this rule only involves an established body
of technical regulations for which frequent and routine amendments are
necessary to keep them operationally current. Unless a written adverse
or negative comment or a written notice of intent to submit an adverse
or negative comment is received within the comment period, the
regulation will become effective on the date specified above. After the
close of the comment period, the FAA will publish a document in the
Federal Register indicating that no adverse or negative comments were
received and confirming the effective date. If the FAA receives, within
the comment period, an adverse or negative comment, or written notice
of intent to submit such a comment, a document withdrawing the direct
final rule will be published in the Federal Register, and a notice of
proposed rulemaking may be published with a new comment period.

Comments Invited

    Although this action is in the form of a direct final rule, and was
not preceded by a notice of proposed rulemaking, interested persons are
invited to comment on this rule by submitting such written data, views,
or arguments as they may desire. An electronic copy of this document
may be downloaded from and comments may be submitted and reviewed at
http://www.regulations.gov. Recently published rule making documents
can also be accessed through the FAA's Web page at http://www.faa.gov
or the Federal Register's Web page at http://www.gpoaccess.gov/fr/
index.html. Communications should identify both docket numbers and be
submitted in triplicate to the address specified under the caption
ADDRESSES above or through the Web site. All communications received on
or before the closing date for comments will be considered, and this
rule may be amended or withdrawn in light of the comments received.
    Comments are specifically invited on the overall regulatory,
economic, environmental, and energy aspects of the rule that might
suggest a need to modify the rule. Factual information that supports
the commenter's ideas and suggestions is extremely helpful in
evaluating the effectiveness of this action and determining whether
additional rulemaking action would be needed. All comments submitted
will be available, both before and after the closing date for comments,
in the Rules Docket for examination by interested persons. Those
wishing the FAA to acknowledge receipt of their comments submitted in
response to this rule must submit a self-addressed, stamped postcard on
which the following statement is made: ``Comments to Docket No. FAA-
2008-0072; Airspace Docket No. 08-ASQ-03.'' The postcard will be date
stamped and returned to the commenter.

The Rule

    This amendment to Title 14, Code of Federal Regulations (14 CFR)
part 71 establishes Class E airspace at Lady Lake, FL providing the
controlled airspace required to support the new Copter Area Navigation
(RNAV) Global Positioning System (GPS) 195 Point in Space (PinS)
instrument approach developed for the Village of Homewood Lady Lake
Hospital. In today's environment where speed of treatment for medical
injuries is imperative, various landing sites have been developed for
helicopter medical Lifeguard flights or Lifeflights; the Village of
Homewood Lady Lake Hospital has been chosen as one of these sites.
Controlled airspace, known as Class E5 airspace, extending upward from
700 feet Above Ground Level (AGL) is required for Instrument Flight
Rule (IFR) operations and to encompass all Instrument Approach
Procedures (IAPs) to the extent practical, therefore, the FAA is
amending Title 14, Code of Federal Regulations (14 CFR) part 71 to
establish a 6-mile radius Class E5 airspace area at Lady Lake, FL.
Designations for Class E airspace areas extending upward from 700 feet
or more above the surface of the Earth are published in FAA Order
7400.9R, signed August 15, 2007 effective September 15, 2007, which is

incorporated by reference in 14 CFR part 71.1. The Class E designations
listed in this document will be published subsequently in the Order.

Agency Findings

    The regulations adopted herein will not have substantial direct
effects on the States, on the relationship between the national
government and the States, or on the distribution of power and
responsibilities among various levels of government. Therefore, it is
determined that this final rule does not have federalism implications
under Executive Order 13132.
    The FAA has determined that this regulation only involves an
established body of technical regulations for which frequent and
routine amendments are necessary to keep them operationally current, is
non-controversial and unlikely to result in adverse or negative
comments. It, therefore, (1) is not a ``significant regulatory action''
under Executive Order 12866; (2) is not a ``significant rule'' under
DOT Regulatory Policies and Procedures (44 FR 11034; February 26,
1979); and (3) does not warrant preparation of a Regulatory Evaluation
as the anticipated impact is so minimal. Since this is a routine matter
that will only affect air traffic procedures and air navigation, it is
certified that this rule, when promulgated, will not have a significant
economic impact on a substantial number of small entities under the
criteria of the Regulatory Flexibility Act.
    The FAA's authority to issue rules regarding aviation safety is
found in Title 49 of the United States Code. Subtitle I, Section 106
describes the authority of the FAA Administrator. Subtitle VII,
Aviation Programs, describes in more detail the scope of the agency's
authority.
    This rule making is promulgated under the authority described in
Subtitle VII, Part A, Subpart I, Section 40103. Under that section, the
FAA is charged with prescribing regulations to assign the use of
airspace necessary to ensure the safety of aircraft and the efficient
use of airspace. This regulation is within the scope of that authority
as it establishes controlled airspace near the Village of Homewood Lady
Lake Hospital in Lady Lake, FL.

Lists of Subjects in 14 CFR Part 71

    Airspace, Incorporation by reference, Navigation (Air).

Adoption of the Amendment:

0
In consideration of the foregoing, the Federal Aviation Administration
amends 14 CFR part 71 as follows:

PART 71--DESIGNATION OF CLASS A, B, C, D, AND E AIRSPACE AREAS; AIR
TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

0
1. The authority citation for part 71 continues to read as follows:

    Authority: 49 U.S.C. 106(g); 40103, 40113, 40120; E.G. 10854, 24
FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

Sec.  71.1  [Amended]

0
2. The incorporation by reference in 14 CFR 71.1 of Federal Aviation.
Administration Order 7400.9R, Airspace Designations and Reporting
Points, signed August 15, 2007, effective September 15, 2007, is
amended as follows:

Paragraph 6005 Class E Airspace Areas Extending Upward from 700 feet
or More Above the Surface of the Earth.
* * * * *

ASO FL E5 Lady Lake, FL [NEW]

Village of Homewood Lady Lake Hospital
    (Lat. 28[deg]56'59'' N., long. 81[deg]57'36'' W.)
Point in Space Coordinates .
    (Lat. 28[deg]57'36'' N., long. 81[deg]57'50'' W.)

    That airspace extending upward from 700 feet above the surface
of the Earth within a 6-mile radius of the Point in Space
Coordinates (Lat. 28[deg]57'36'' N., long. 81[deg]57'50'' W.)
serving the Village of Homewood Lady Lake Hospital.
* * * * *

    Issued in College Park, Georgia, on February 26, 2008.
Mark D. Ward,
Manager, System Support Group, Eastern Service Center.
[FR Doc. E8-5603 Filed 3-20-08; 8:45 am]

BILLING CODE 4910-13-M


October 9, 2003

Wayne:

Enclose  is a modified version of the Antidegradation Policy including some

of  your  comments.   As  we  told  you,  this document will be part of the

PR-Water Quality Standards Regulation (WQSR).  So we understand that may be

with  a  reference  to the applicable Sections of the WQSR we could address

some  of  your  comments, especially those regarding to part IV-a-ii-2.  In

addition  we  want  to clarify that our intention with that statement is to

avoid  that one discharge could compromise all the assimilative capacity of

the receiving water body if really it does not need it.  We could allow the

use   of  additional  assimilative  capacity  as  long  as  the  petitioner

demonstrate  to  this  Board the real necessity of such additional capacity

and  demonstrate  compliance  with  the  applicable  provisions of the WQSR

(mixing  zones,  waste  load  allocations,  and  so on).  Also, previous to

submit  to EQB a water quality certificate application, the discharger must

comply  with  Article  4-C of Law 9 of June 18, 1970, this is regarding the

Environmental  Impact  Statement  (EIS) process.  During the EIS process an

alternative analysis, including the no action, and a socioeconomic analysis

are performed.

Regarding  your  comment to part IV-a-ii-1-b that EQB has to define what it

considers  a  significant lowering of water quality, our threshold point is

compliance  with  the  applicable  water quality standards at the receiving

water body.  In the case of discharges with effluent limitations based on a

mixing  zone  or  waste load allocation, EQB will allow some non-compliance

with  the  water  quality  standards in the receiving water body but at the

edge  of  the  mixing  zone or the immediate vicinity of the discharge, the

water  body  has  to  meet  compliance  with  the  applicable water quality

standards as established on Articles 5 and 10 of the WQSR.

If  you have any question or comment do not hesitate to contact me at phone

number<PHONE_NUMBER> extension 2500 or<PHONE_NUMBER>.

Annette Feliberty Ruiz

(See    attached    file:   EQB   Antidegradation   Policy   Implementation

Procedure-3.doc)


[Federal Register Volume 80, Number 120 (Tuesday, June 23, 2015)]
[Notices]
[Pages 36014-36015]
[FR Doc No: 2015-15449]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

Sunshine Act Meeting

    Notice is hereby given, pursuant to the provisions of the
Government in the Sunshine Act, Public Law 94-409, that the Securities
and Exchange Commission will hold a Closed Meeting on Thursday, June
25, 2015 at 2:00 p.m.
    Commissioners, Counsel to the Commissioners, the Secretary to the
Commission, and recording secretaries will attend the Closed Meeting.
Certain

staff members who have an interest in the matters also may be present.
    The General Counsel of the Commission, or her designee, has
certified that, in her opinion, one or more of the exemptions set forth
in 5 U.S.C. 552b(c)(3), (5), (7), 9(B) and (10) and 17 CFR
200.402(a)(3), (a)(5), (a)(7), (a)(9)(ii) and (a)(10), permit
consideration of the scheduled matter at the Closed Meeting.
    Commissioner Piwowar, as duty officer, voted to consider the items
listed for the Closed Meeting in closed session.
    The subject matter of the Closed Meeting will be:
Institution and settlement of injunctive actions;
Institution and settlement of administrative proceedings;
Resolution of litigation claims; and
Other matters relating to enforcement proceedings.
    At times, changes in Commission priorities require alterations in
the scheduling of meeting items.
    For further information and to ascertain what, if any, matters have
been added, deleted, or postponed, please contact the Office of the
Secretary at<PHONE_NUMBER>.

    Dated: June 18, 2015.
Brent J. Fields,
Secretary.
[FR Doc. 2015-15449 Filed 6-19-15; 11:15 am]
 BILLING CODE 8011-01-P


[Federal Register Volume 85, Number 158 (Friday, August 14, 2020)]
[Notices]
[Pages 49696-49697]
[FR Doc No: 2020-17756]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-89514; File No. SR-CBOE-2020-055]

Self-Regulatory Organizations; Cboe Exchange, Inc.; Notice of
Designation of a Longer Period for Commission Action on a Proposed Rule
Change, as Modified by Amendment No. 1, To Amend Rule 5.24

August 10, 2020.
    On June 12, 2020, Cboe Exchange, Inc. (the ``Exchange'' or ``Cboe
Options'') filed with the Securities and Exchange Commission
(``Commission''), pursuant to Section 19(b)(1) of the Securities
Exchange Act of 1934 (``Act'') \1\ and Rule 19b-4 thereunder,\2\ a
proposed rule change to amend Rule 5.24 by permitting a virtual trading
floor as a business continuity and disaster recovery plan. The proposed
rule change was published for comment in the Federal Register on June
29, 2020.\3\ On July 23, 2020, the Exchange filed Amendment No. 1 to
the proposed rule change.\4\ The Commission has received one comment
letter on the proposed rule change.\5\
---------------------------------------------------------------------------

    \1\ 15 U.S.C.78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ See Securities Exchange Act Release No. 89131 (June 23,
2020), 85 FR 38951.
    \4\ In Amendment No. 1, the Exchange clarified that the
temporary all-electronic trading rules set forth in Rule 5.24(e)(1)
would not apply to classes engaged in the virtual trading floor. The
Exchange also amended the proposal to permit clerks to access the
virtual trading floor. When the Exchange filed Amendment No. 1 to
CBOE-2020-055, it also submitted the text of the amendment as a
comment letter to the filing, which the Commission made publicly
available at https://www.sec.gov/comments/sr-cboe-2020-055/srcboe2020055-7470763-221281.pdf.
    \5\ See letter to Secretary, Commission, from Kevin Kennedy,
Senior Vice President, Nasdaq, dated July 10, 2020, available at
https://www.sec.gov/comments/sr-cboe-2020-055/srcboe2020055-7409704-219196.pdf.
---------------------------------------------------------------------------

    Section 19(b)(2) of the Act \6\ provides that, within 45 days of
the publication of notice of the filing of a proposed rule change, or
within such longer period up to 90 days as the Commission may designate
if it finds such longer period

to be appropriate and publishes its reasons for so finding, or as to
which the self-regulatory organization consents, the Commission shall
either approve the proposed rule change, disapprove the proposed rule
change, or institute proceedings to determine whether the proposed rule
change should be disapproved. The 45th day after publication of the
notice for this proposed rule change is August 13, 2020.
---------------------------------------------------------------------------

    \6\ 15 U.S.C. 78s(b)(2).
---------------------------------------------------------------------------

    The Commission is extending this 45-day time period. The Commission
finds that it is appropriate to designate a longer period within which
to take action on the proposal so that it has sufficient time to
consider the proposed rule change, as modified by Amendment No. 1.
Accordingly, the Commission, pursuant to Section 19(b)(2) of the
Act,\7\ designates September 27, 2020, as the date by which the
Commission shall either approve or disapprove, or institute proceedings
to determine whether to disapprove, the proposed rule change (File No.
SR-CBOE-2020-055), as modified by Amendment No. 1.
---------------------------------------------------------------------------

    \7\ Id.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\8\
---------------------------------------------------------------------------

    \8\ 17 CFR 200.30-3(a)(31).
---------------------------------------------------------------------------

J. Matthew DeLesDernier,
Assistant Secretary.
[FR Doc. 2020-17756 Filed 8-13-20; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 80, Number 230 (Tuesday, December 1, 2015)]
[Notices]
[Pages 75092-75093]
[FR Doc No: 2015-30425]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice Of Filings #3

    Take notice that the Commission received the following electric
rate filings:
    Docket Numbers: ER13-94-006.
    Applicants: Avista Corporation.
    Description: Compliance filing: Avista Corp OATT Order 1000
Compliance Filing to be effective 11/24/2015.
    Filed Date: 11/23/15.
    Accession Number: 20151123-5202.
    Comments Due: 5 p.m. ET 12/14/15.

    Docket Numbers: ER13-99-007.
    Applicants: Puget Sound Energy, Inc.
    Description: Compliance filing: OATT Order No. 1000 Compliance
Filing to be effective 11/24/2015.
    Filed Date: 11/23/15.
    Accession Number: 20151123-5287.
    Comments Due: 5 p.m. ET 12/14/15.

    Docket Numbers: ER13-836-006.
    Applicants: MATL LLP.
    Description: Compliance filing: Compliance Filing Schedule K to be
effective 11/24/2015.
    Filed Date: 11/23/15.
    Accession Number: 20151123-5290.
    Comments Due: 5 p.m. ET 12/14/15.

    Docket Numbers: ER15-422-002.
    Applicants: Avista Corporation.
    Description: Compliance filing: Avista Corp Order 1000 FERC Rate
Schedule No. CG2 Compliance Filing to be effective 11/24/2015.
    Filed Date: 11/23/15.
    Accession Number: 20151123-5201.
    Comments Due: 5 p.m. ET 12/14/15.

    Docket Numbers: ER15-429-003.
    Applicants: Puget Sound Energy, Inc.
    Description: Compliance filing: Columbia Grid Functional Agreement
Second Amendment to be effective 11/24/2015.
    Filed Date: 11/23/15.
    Accession Number: 20151123-5288.
    Comments Due: 5 p.m. ET 12/14/15.

    Docket Numbers: ER15-2533-001.
    Applicants: Midcontinent Independent System Operator, Inc.
    Description: Compliance filing: 2015-11-23_SA 2831 ITC-Geronimo GIA
Compliance (J340) to be effective 10/25/2015.
    Filed Date: 11/23/15.
    Accession Number: 20151123-5203.
    Comments Due: 5 p.m. ET 12/14/15.

    Docket Numbers: ER16-381-000.
    Applicants: New York State Electric & Gas Corporation.
    Description: Sec.  205(d) Rate Filing: Executed Services Agreement
with FirstEnergy Service Company to be effective 10/23/2015.
    Filed Date: 11/23/15.
    Accession Number: 20151123-5226.
    Comments Due: 5 p.m. ET 12/14/15.

    Docket Numbers: ER16-382-000.
    Applicants: Dominion Retail, Inc.
    Description: Tariff Cancellation: Cancellation of Tariff and Tariff
I.D. to be effective 11/24/2015.
    Filed Date: 11/23/15.
    Accession Number: 20151123-5284.
    Comments Due: 5 p.m. ET 12/14/15.

    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern

time on the specified comment date. Protests may be considered, but
intervention is necessary to become a party to the proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: November 23, 2015.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2015-30425 Filed 11-30-15; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 87, Number 236 (Friday, December 9, 2022)]
[Notices]
[Page 75619]
[FR Doc No: 2022-26843]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Effectiveness of Exempt Wholesale Generator and Foreign
Utility Company Status

------------------------------------------------------------------------
                                                      Docket Nos.
------------------------------------------------------------------------
Eastover Solar LLC...........................  EG22-215-000
PGR 2021 Lessee 17, LLC......................  EG22-216-000
Yellow Pine Solar, LLC.......................  EG22-217-000
Mesquite Solar 4, LLC........................  EG22-218-000
Mesquite Solar 5, LLC........................  EG22-219-000
Fall River Solar, LLC........................  EG22-220-000
DLS--Jean Duluth Project Co, LLC.............  EG22-221-000
DLS--Laskin Project Co, LLC..................  EG22-222-000
DLS--Sylvan Project Co, LLC..................  EG22-223-000
GulfStar Power, LLC..........................  EG22-224-000
Yellowbud Solar, LLC.........................  EG22-225-000
Jicarilla Solar 1 LLC........................  EG22-226-000
Jicarilla Storage 1 LLC......................  EG22-227-000
Colice Hall Solar, LLC.......................  EG22-228-000
I Squared Capital............................  FC22-3-000
------------------------------------------------------------------------

    Take notice that during the month of November 2022, the status of
the above-captioned entities as Exempt Wholesale Generators or Foreign
Utility Companies became effective by operation of the Commission's
regulations. 18 CFR 366.7(a) (2021).

    Dated: December 1, 2022.
Kimberly D. Bose,
Secretary.
[FR Doc. 2022-26843 Filed 12-8-22; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 87, Number 221 (Thursday, November 17, 2022)]
[Notices]
[Pages 69032-69034]
[FR Doc No: 2022-25001]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-2672]

Draft Amended Environmental Assessment for Production of
AquAdvantage Salmon at the Bay Fortune and Rollo Bay Facilities on
Prince Edward Island, Canada; Availability; Request for Comments

AGENCY: Food and Drug Administration, Department of Health and Human
Services (HHS).

ACTION: Notice of availability; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing the availability of a document entitled ``Draft Amended
Environmental Assessment for Production of AquAdvantage Salmon at the
Bay Fortune and Rollo Bay Facilities on Prince Edward Island, Canada.''
This draft amended environmental assessment (EA) has been prepared by
FDA in support of the approved new animal drug application (NADA 141-
454) concerning AquAdvantage Salmon (AAS), in response to an order by
the U.S. District Court, Northern District of California.

DATES: Submit either electronic or written comments on the draft
amended EA by January 17, 2023.

ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of January 17, 2023. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are received on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked, and identified
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2022-N-2672 for ``Draft Amended Environmental Assessment for
Production of AquAdvantage Salmon at the Bay Fortune and Rollo Bay
Facilities on Prince Edward Island, Canada.'' Received comments will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments, and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Holly Zahner, Center for Veterinary
Medicine (HFV-162), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855,<PHONE_NUMBER>, [email protected].

SUPPLEMENTARY INFORMATION:

I. Background and Purpose

    FDA is announcing the availability of a document entitled ``Draft
Amended Environmental Assessment for Production of AquAdvantage Salmon
at the Bay Fortune and Rollo Bay Facilities on Prince Edward Island,
Canada.'' This draft amended EA has been prepared by FDA in support of
the approved application (NADA 141-454) concerning AAS, in response to
an order by the U.S. District Court, Northern District of California,
issued on November 5, 2020; Inst. for Fisheries Res. v. U.S. Food and
Drug Admin, 499 F. Supp. 3d 657, 660 (N.D. Cal. 2020) and is available
in the docket or at https://www.fda.gov/animal-veterinary/workshops-conferences-meetings/virtual-public-meeting-aquadvantage-salmon-draft-amended-environmental-assessment-12152022.
    On November 19, 2015, FDA approved NADA 141-454 concerning AAS,
owned by AquaBounty Technologies (ABT). AAS are triploid, hemizygous,
all-female Atlantic salmon (Salmo salar) bearing a single copy of the
[alpha]-form of the opAFP-GHc2 recombinant DNA (rDNA) construct at the
[alpha]-locus in the E.O.-1[alpha] lineage. AAS is designed to exhibit
a rapid-growth phenotype. The November 19, 2015, NADA approval allowed
for the AAS to be produced at a facility on Prince Edward Island (PEI),
Canada, and grown at a facility in Panama (that has subsequently
closed) and allowed for sale of food harvested from AAS in the United
States.
    As a part of the NADA review process under the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 321, et seq.), and consistent with the
mandates in the National Environmental Policy Act of 1969 (NEPA) (42
U.S.C. 4321, et seq.) and FDA's environmental impact considerations
regulations (21 CFR part 25), FDA's Center for Veterinary Medicine
prepared an EA dated November 12, 2015, for the original approval of
the rDNA construct as integrated in the genome of AAS. Based on the
2015 EA and the specific conditions that were established in the NADA,
FDA determined the action would not individually or cumulatively have a
significant effect on the quality of the human environment in the
United States. Therefore, FDA prepared a finding of no significant
impact (FONSI). Based on the findings in the 2015 EA, FDA also made a
``no effect'' determination under the Endangered Species Act (ESA) (16
U.S.C. 1531, et seq.), concluding that AAS, when produced and reared
under the conditions in the application, and as described in the 2015
EA, would not jeopardize the continued existence of U.S. populations of
threatened or endangered Atlantic salmon or result in the destruction
or adverse modification of their critical habitat.
    Subsequently, several organizations filed suit in the U.S. District
Court, Northern District of California, challenging, among other
things, FDA's evaluations under NEPA and the ESA for the 2015 NADA
approval. On November 5, 2020, the Court found that ``FDA did not . . .
meaningfully analyze what might happen to normal salmon in the event
the engineered salmon did survive and establish themselves in the wild.
Even if this scenario was unlikely, the FDA was still required to
assess the consequences of it coming to pass.'' The

Court ordered FDA to complete the analysis and reconsider its ``no
effect'' determination under the ESA together with a revised NEPA
evaluation. See Inst. for Fisheries Res. v. U.S. Food and Drug Admin,
499 F. Supp. 3d 657, 660. However, the Court did not vacate the
approval; the approval is still in effect.
    To address the November 5, 2020, Court opinion, we have prepared a
draft amended EA, entitled ``Draft Amended Environmental Assessment for
Production of AquAdvantage Salmon at the Bay Fortune and Rollo Bay
Facilities on Prince Edward Island, Canada.'' We request that the
public review the draft amended EA and submit comments to the docket.
    In this draft amended EA, we have expanded our assessment beyond
that in the 2015 EA to include an exhaustive analysis of the likelihood
and severity of harms that could occur if AAS and AquAdvantage
broodstock (collectively referred to in the amended EA as AquaBounty
Technology (ABT) Salmon) are assumed to be present in the U.S. aquatic
environment. We outline the pathways necessary for ABT Salmon to escape
confinement from the PEI facilities and migrate to and establish a
persistent population in the United States. We also evaluate the
potential pathways for disease (including pathogen and parasite)
transmission from ABT Salmon and from the production of ABT Salmon at
facilities on PEI to wild fish populations. In addition, we identify
and evaluate the potential harms (consequences) to the U.S. environment
and the endangered Atlantic salmon of the Gulf of Maine Distinct
Population Segment if these highly unlikely scenarios were to occur.
Finally, we revisit whether there is a potential for significant
impacts on the U.S. environment under NEPA, and whether the action
could result in effects on threatened and endangered Atlantic salmon
and their critical habitat in the United States under the ESA.
Ultimately, this analysis will aid the Agency in the decision of
whether to prepare a FONSI or an environmental impact statement.
    We note that the information and analyses in the draft amended EA
reflect comments and input received from the National Marine Fisheries
Service and the Fish and Wildlife Service during a recent ESA technical
assistance review initiated in June 2022 with initial discussions
beginning in March 2021. FDA intends to initiate an informal
consultation with the services after the close of the public comment
period if the current conclusions with respect to the ESA are not
altered.
    Elsewhere in this issue of the Federal Register, we are providing
notice of a virtual public meeting on December 15, 2022. Further
information, including the time the meeting will start, the agenda, and
how to register to attend the meeting, can be found at https://www.fda.gov/animal-veterinary/workshops-conferences-meetings/virtual-public-meeting-aquadvantage-salmon-draft-amended-environmental-assessment-12152022.

II. Topics for Comment Regarding the Draft Amended EA

    The Agency is placing the draft amended EA on public display at the
Dockets Management Staff (see DATES and ADDRESSES) and at https://www.fda.gov/animal-veterinary/workshops-conferences-meetings/virtual-public-meeting-aquadvantage-salmon-draft-amended-environmental-assessment-12152022 for public review and comment for 60 days.
    Comments should be limited to the draft amended EA only, as
described below. We will not review comments outside of the scope of
the draft amended EA such as AquAdvantage Salmon generally or the
approved application. Given that FDA must comply with a court order and
that the public can comment both by submitting comments to the docket
and by participating in the public meeting, FDA believes that a 60-day
comment period is appropriate and does not intend to grant requests for
extension of the comment period.
    We are particularly interested in receiving comments from the
public on the following:
    1. Is the expanded conceptual model for risk assessment (Figure 4-
1) in the draft amended EA complete?
    2. Are the risk-related questions (Section 4.4) appropriate given
the new expanded conceptual model?
    3. Are there any exposure pathways to the U.S. environment that
were not identified or evaluated in the draft amended EA?
    4. Are there any potential harms (adverse consequences, effects, or
impacts) to the U.S. environment from ABT Salmon that were not
identified or evaluated in the draft amended EA?
    5. Are there any potential environmental impacts on endangered
Atlantic salmon or their critical habitat in the United States that
were not identified or evaluated in the draft amended EA?

    Dated: November 10, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-25001 Filed 11-16-22; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register: October 14, 2010 (Volume 75, Number 198)]
[Rules and Regulations]
[Page 63066-63067]
[DOCID:fr14oc10-13]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2010-0634; Airspace Docket No. 10-AWP-8]

Establishment of Class E Airspace; Clifton/Morenci, AZ

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This action will establish Class E airspace at Greenlee County
Airport, Clifton/Morenci, AZ, to accommodate aircraft using new Area
Navigation (RNAV) Global Positioning System (GPS) Standard Instrument
Approach Procedures (SIAPs) at Greenlee County Airport. This will
improve the safety and management of Instrument Flight Rules (IFR)
operations at the airport.

DATES: Effective date, 0901 UTC, January 13, 2011. The Director of the
Federal Register approves this incorporation by reference action under
1 CFR part 51, subject to the annual revision of FAA Order 7400.9 and
publication of conforming amendments.

FOR FURTHER INFORMATION CONTACT: Eldon Taylor, Federal Aviation
Administration, Operations Support Group, Western Service Center, 1601
Lind Avenue, SW., Renton, WA 98057; telephone<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

History

    On July 29, 2010, the FAA published in the Federal Register a
notice of proposed rulemaking to establish controlled airspace at
Clifton/Morenci, AZ (75 FR 44725). Interested parties were invited to
participate in this rulemaking effort by submitting written comments on
the proposal to the FAA. No comments were received.
    Class E airspace designations are published in paragraph 6005 of
FAA Order 7400.9U dated August 18, 2010, and effective September 15,
2010, which is incorporated by reference in 14 CFR Part 71.1. The Class
E airspace designations listed in this document will be published
subsequently in that Order.

The Rule

    This action amends Title 14 Code of Federal Regulations (14 CFR)
Part 71 by establishing Class E airspace extending upward from 700 feet
above the surface, at Greenlee County Airport, Clifton/Morenci, CA, to
accommodate IFR aircraft executing new RNAV (GPS) SIAPs at the airport.
This action is necessary for the safety and management of IFR
operations.
    The FAA has determined this regulation only involves an established
body of technical regulations for which frequent and routine amendments
are necessary to keep them operationally current. Therefore, this
regulation: (1) Is not a ``significant regulatory action'' under
Executive Order 12866; (2) is not a ``significant rule'' under DOT

Regulatory Policies and Procedures (44 FR 11034; February 26, 1979);
and (3) does not warrant preparation of a regulatory evaluation as the
anticipated impact is so minimal. Since this is a routine matter that
will only affect air traffic procedures and air navigation, it is
certified this rule, when promulgated, will not have a significant
economic impact on a substantial number of small entities under the
criteria of the Regulatory Flexibility Act. The FAA's authority to
issue rules regarding aviation safety is found in Title 49 of the U.S.
Code. Subtitle 1, section 106 discusses the authority of the FAA
Administrator. Subtitle VII, Aviation Programs, describes in more
detail the scope of the agency's authority. This rulemaking is
promulgated under the authority described in subtitle VII, part A,
subpart I, section 40103. Under that section, the FAA is charged with
prescribing regulations to assign the use of airspace necessary to
ensure the safety of aircraft and the efficient use of airspace. This
regulation is within the scope of that authority as it establishes
controlled airspace at Greenlee County Airport, Clifton/Morenci, AZ.

List of Subjects in 14 CFR Part 71

    Airspace, Incorporation by reference, Navigation (air).

Adoption of the Amendment

0
In consideration of the foregoing, the Federal Aviation Administration
amends 14 CFR part 71 as follows:

PART 71--DESIGNATION OF CLASS A, B, C, D AND E AIRSPACE AREAS; AIR
TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

0
1. The authority citation for 14 CFR part 71 continues to read as
follows:

    Authority:  49 U.S.C. 106(g), 40103, 40113, 40120; E. O. 10854,
24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

Sec.  71.1  [Amended]

0
2. The incorporation by reference in 14 CFR Part 71.1 of the Federal
Aviation Administration Order 7400.9U, Airspace Designations and
Reporting Points, dated August 18, 2010, and effective September 15,
2010 is amended as follows:

Paragraph 6005 Class E airspace areas extending upward from 700
feet or more above the surface of the earth.

* * * * *

AWP AZ E5 Clifton/Morenci, AZ [New]

Greenlee County Airport, AZ
    (Lat. 32[deg]57'25'' N., long. 109[deg]12'40'' W.)

That airspace extending from 700 feet above the surface within a
6.5-mile radius of Greenlee County Airport.

    Issued in Seattle, Washington, on October 4, 2010.
John Warner,
Manager, Operations Support Group, Western Service Center.
[FR Doc. 2010-25835 Filed 10-13-10; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 82, Number 107 (Tuesday, June 6, 2017)]
[Notices]
[Pages 26211-26217]
[FR Doc No: 2017-11640]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2017-0035]

Qualification of Drivers; Exemption Applications; Diabetes
Mellitus

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of applications for exemptions; request for comments.

-----------------------------------------------------------------------

SUMMARY: FMCSA announces receipt of applications from 42 individuals
for exemption from the prohibition against persons with insulin-treated
diabetes mellitus (ITDM) operating commercial motor vehicles (CMVs) in
interstate commerce. If granted, the exemptions would enable these
individuals with ITDM to operate CMVs in interstate commerce.

DATES: Comments must be received on or before July 6, 2017.

ADDRESSES: You may submit comments bearing the Federal Docket
Management System (FDMS) Docket No. FMCSA-2017-0035 using any of the
following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the on-line instructions for submitting
comments.
     Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue SE., West Building Ground Floor,
Room W12-140, Washington, DC 20590-0001.
     Hand Delivery: West Building Ground Floor, Room W12-140,
1200 New Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m.,
e.t., Monday through Friday, except Federal Holidays.
     Fax: 1-202-493-2251.
    Instructions: Each submission must include the Agency name and the
docket numbers for this notice. Note that all comments received will be
posted without change to http://www.regulations.gov, including any
personal information provided. Please see the Privacy Act heading below
for further information.
    Docket: For access to the docket to read background documents or
comments, go to http://www.regulations.gov at any time or Room W12-140
on the ground level of the West Building, 1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5 p.m., e.t., Monday through Friday,
except Federal holidays. The Federal Docket Management System (FDMS) is
available 24 hours each day, 365 days each year. If you want
acknowledgment that we received your comments, please include a self-
addressed, stamped envelope or postcard or print the acknowledgement
page that appears after submitting comments on-line.
    Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to www.regulations.gov, as described in the
system of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.dot.gov/privacy.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division,<PHONE_NUMBER><EMAIL_ADDRESS>FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE., Room W64-113,
Washington, DC 20590-0001. Office hours are 8:30 a.m. to 5 p.m., e.t.,
Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION:

I. Background

    Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption
from the Federal Motor Carrier Safety Regulations for a 2-year period
if it finds ``such exemption would likely achieve a level of safety
that is equivalent to or greater than the level that would be achieved
absent such exemption.'' The statute also allows the Agency to renew
exemptions at the end of the 2-year period. The 42 individuals listed
in this notice have recently requested such an exemption from the
diabetes prohibition in 49 CFR 391.41(b)(3), which applies to drivers
of CMVs in interstate commerce. Accordingly, the Agency will evaluate
the qualifications of each applicant to determine whether granting the
exemption will achieve the required level of safety mandated by
statute.

II. Qualifications of Applicants

Shayne T. Anthony

    Mr. Anthony, 38, has had ITDM since 2006. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Anthony understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Anthony meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he does not
have diabetic retinopathy. He holds an operator's license from
Maryland.

Steven S. Arrowood

    Mr. Arrowood, 39, has had ITDM since 2001. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Arrowood understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Arrowood meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Mississippi.

Melyssia V. Auwerda

    Ms. Auwerda, 28, has had ITDM since 2000. Her endocrinologist
examined her in 2017 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
Her endocrinologist certifies that Ms. Auwerda understands diabetes
management and monitoring has stable control of her diabetes using
insulin, and is able to drive a CMV safely. Ms. Auwerda meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). Her
ophthalmologist examined her in 2016 and certified that she does not
have diabetic retinopathy. She holds a Class A CDL from Colorado.

Jerome Barfield

    Mr. Barfield, 52, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Barfield understands diabetes
management and monitoring,

has stable control of his diabetes using insulin, and is able to drive
a CMV safely. Mr. Barfield meets the requirements of the vision
standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in
2016 and certified that he does not have diabetic retinopathy. He holds
an operator's license from Georgia.

Grover C. Binkley

    Mr. Binkley, 49, has had ITDM since 2007. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Binkley understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Binkley meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he does not
have diabetic retinopathy. He holds an operator's license from
Tennessee.

Vincent Bongiovanni

    Mr. Bongiovanni, 47, has had ITDM since 1992. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Bongiovanni understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Bongiovanni meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he has stable
nonproliferative diabetic retinopathy. He holds an operator's license
from Massachusetts.

Robert H. Branyon

    Mr. Branyon, 63, has had ITDM since 2003. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Branyon understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Branyon meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class B CDL from
South Carolina.

Gary L. Brown

    Mr. Brown, 61, has had ITDM since 2012. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Brown understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Brown meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Indiana.

Douglas R. Carr

    Mr. Carr, 64, has had ITDM since 2013. His endocrinologist examined
him in 2016 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Carr understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Carr meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2017 and certified that he has stable nonproliferative diabetic
retinopathy. He holds an operator's license from California.

Gary F. Cartwright

    Mr. Cartwright, 65, has had ITDM since 2016. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Cartwright understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Cartwright meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Wisconsin.

Jeffrey R. Cline

    Mr. Cline, 52, has had ITDM since 2010. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Cline understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Cline meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Ohio.

Cheryl L. Coffman

    Ms. Coffman, 50, has had ITDM since 2008. Her endocrinologist
examined her in 2017 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
Her endocrinologist certifies that Ms. Coffman understands diabetes
management and monitoring has stable control of her diabetes using
insulin, and is able to drive a CMV safely. Ms. Coffman meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). Her
ophthalmologist examined her in 2016 and certified that she does not
have diabetic retinopathy. She holds a Class B CDL from Indiana.

Jay B. Cole

    Mr. Cole, 32, has had ITDM since 2016. His endocrinologist examined
him

in 2016 and certified that he has had no severe hypoglycemic reactions
resulting in loss of consciousness, requiring the assistance of another
person, or resulting in impaired cognitive function that occurred
without warning in the past 12 months and no recurrent (2 or more)
severe hypoglycemic episodes in the last 5 years. His endocrinologist
certifies that Mr. Cole understands diabetes management and monitoring,
has stable control of his diabetes using insulin, and is able to drive
a CMV safely. Mr. Cole meets the requirements of the vision standard at
49 CFR 391.41(b)(10). His optometrist examined him in 2017 and
certified that he does not have diabetic retinopathy. He holds a Class
A CDL from Texas.

Nicholas B. Cooksey

    Mr. Cooksey, 23, has had ITDM since 1999. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Cooksey understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Cooksey meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds an operator's license from California.

Michael Csaplik

    Mr. Csaplik, 62, has had ITDM since 2015. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Csaplik understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Csaplik meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Iowa.

Karl J. Dence

    Mr. Dence, 48, has had ITDM since 2012. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Dence understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Dence meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from New
York.

James R. Diem

    Mr. Diem, 65, has had ITDM since 2013. His endocrinologist examined
him in 2017 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Diem understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Diem meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2017 and certified that he has stable nonproliferative diabetic
retinopathy. He holds a Class A CDL from Pennsylvania.

Mark W. Eaves

    Mr. Eaves, 49, has had ITDM since 2014. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Eaves understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Eaves meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from New York.

Franklin J. Economy

    Mr. Economy, 62, has had ITDM since 2012. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Economy understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Economy meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Pennsylvania.

Ervin L. Elfman, Jr.

    Mr. Elfman, 79, has had ITDM since 2015. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Elfman understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Elfman meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Kansas.

Oliver L. Grigsby

    Mr. Grigsby, 59, has had ITDM since 2014. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Grigsby understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Grigsby meets the
requirements of the vision standard at

49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and
certified that he does not have diabetic retinopathy. He holds a Class
A CDL from Virginia.

Jason Hargrove

    Mr. Hargrove, 51, has had ITDM since 2014. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Hargrove understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Hargrove meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he has stable
proliferative diabetic retinopathy. He holds a Class A CDL from North
Carolina.

Kevin J. Hart

    Mr. Hart, 63, has had ITDM since 1997. His endocrinologist examined
him in 2017 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Hart understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Hart meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2017 and certified that he does not have diabetic retinopathy. He
holds an operator's license from New York.

Thomas R. Holland

    Mr. Holland, 24, has had ITDM since 1995. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Holland understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Holland meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he does not
have diabetic retinopathy. He holds an operator's license from
Maryland.

Martin J. Jones

    Mr. Jones, 52, has had ITDM since 2015. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Jones understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Jones meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class B CDL from Massachusetts.

Robert A. Kurley

    Mr. Kurley, 47, has had ITDM since 2015. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Kurley understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Kurley meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he does not
have diabetic retinopathy. He holds a Class B CDL from Pennsylvania.

Robert I. Leach

    Mr. Leach, 65, has had ITDM since 2016. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Leach understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Leach meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Virginia.

Mark A. Long

    Mr. Long, 56, has had ITDM since 2016. His endocrinologist examined
him in 2017 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Long understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Long meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2017 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Pennsylvania.

Micheal D. Lucas

    Mr. Lucas, 66, has had ITDM since 1998. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Lucas understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Lucas meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Ohio.

Dagmar L. Osoria Castaneda

    Mr. Osorio Castaneda, 31, has had ITDM since 2015. His
endocrinologist examined him in 2016 and certified that he has had no
severe hypoglycemic reactions resulting in loss of consciousness,
requiring the assistance of another person, or resulting in impaired
cognitive function that occurred without warning in the past 12 months
and no recurrent (2 or more) severe hypoglycemic episodes in the last 5
years. His endocrinologist certifies

that Mr. Osorio Castaneda understands diabetes management and
monitoring, has stable control of his diabetes using insulin, and is
able to drive a CMV safely. Mr. Osorio Castaneda meets the requirements
of the vision standard at 49 CFR 391.41(b)(10). His optometrist
examined him in 2017 and certified that he does not have diabetic
retinopathy. He holds an operator's license from California.

Roxanne Pierce

    Ms. Pierce, 62, has had ITDM since 1997. Her endocrinologist
examined her in 2017 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
Her endocrinologist certifies that Ms. Pierce understands diabetes
management and monitoring, has stable control of her diabetes using
insulin, and is able to drive a CMV safely. Ms. Pierce meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). Her
optometrist examined her in 2017 and certified that she does not have
diabetic retinopathy. She holds an operator's license from North
Dakota.

Garry B. Reynolds, Jr.

    Mr. Reynolds, 52, has had ITDM since 2016. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Reynolds understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Reynolds meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class C CDL from Michigan.

Jason R. Roberts

    Mr. Roberts, 38, has had ITDM since 1994. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Roberts understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Roberts meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class D CDL from
Kentucky.

Ronald H. Shepherd

    Mr. Shepherd, 41, has had ITDM since 2017. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Shepherd understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Shepherd meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Ohio.

Randall D. Shiflett

    Mr. Shiflett, 52, has had ITDM since 2016. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Shiflett understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Shiflett meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from West Virginia.

Teddy D. Smith

    Mr. Smith, 50, has had ITDM since 2015. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Smith understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Smith meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Oklahoma.

Jonathan D. Snudden, Jr.

    Mr. Snudden, 48, has had ITDM since 2013. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Snudden understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Snudden meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Missouri.

Maleika A. Swain-Ogilvie

    Ms. Swain-Ogilvie, 38, has had ITDM since 2016. Her endocrinologist
examined her in 2016 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
Her endocrinologist certifies that Ms. Swain-Ogilvie understands
diabetes management and monitoring has stable control of her diabetes
using insulin, and is able to drive a CMV safely. Ms. Swain-Ogilvie
meets the requirements of the vision standard at 49 CFR 391.41(b)(10).
Her ophthalmologist examined her in 2016 and certified that she does
not have diabetic retinopathy. She holds a Class B CDL from
Pennsylvania.

Ashley D. Waite

    Mr. Waite, 64, has had ITDM since 2007. His endocrinologist
examined him

in 2017 and certified that he has had no severe hypoglycemic reactions
resulting in loss of consciousness, requiring the assistance of another
person, or resulting in impaired cognitive function that occurred
without warning in the past 12 months and no recurrent (2 or more)
severe hypoglycemic episodes in the last 5 years. His endocrinologist
certifies that Mr. Waite understands diabetes management and
monitoring, has stable control of his diabetes using insulin, and is
able to drive a CMV safely. Mr. Waite meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2016 and certified that he does not have diabetic retinopathy.
He holds a Class A CDL from Vermont.

Delbert A. Walker

    Mr. Walker, 64, has had ITDM since 2015. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Walker understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Walker meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Pennsylvania.

Terry L. Watkins

    Mr. Watkins, 49, has had ITDM since 2008. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Watkins understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Watkins meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from West Virginia.

Timothy Zulla

    Mr. Zulla, 54, has had ITDM since 2015. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Zulla understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Zulla meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Florida.

III. Request for Comments

    In accordance with 49 U.S.C. 31136(e) and 31315, FMCSA requests
public comment from all interested persons on the exemption petitions
described in this notice. We will consider all comments received before
the close of business on the closing date indicated in the date section
of the notice.
    FMCSA notes that section 4129 of the Safe, Accountable, Flexible
and Efficient Transportation Equity Act: A Legacy for Users requires
the Secretary to revise its diabetes exemption program established on
September 3, 2003 (68 FR 52441).\1\ The revision must provide for
individual assessment of drivers with diabetes mellitus, and be
consistent with the criteria described in section 4018 of the
Transportation Equity Act for the 21st Century (49 U.S.C. 31305).
---------------------------------------------------------------------------

    \1\ Section 4129(a) refers to the 2003 notice as a ``final
rule.'' However, the 2003 notice did not issue a ``final rule'' but
did establish the procedures and standards for issuing exemptions
for drivers with ITDM.
---------------------------------------------------------------------------

    Section 4129 requires: (1) Elimination of the requirement for 3
years of experience operating CMVs while being treated with insulin;
and (2) establishment of a specified minimum period of insulin use to
demonstrate stable control of diabetes before being allowed to operate
a CMV.
    In response to section 4129, FMCSA made immediate revisions to the
diabetes exemption program established by the September 3, 2003 notice.
FMCSA discontinued use of the 3-year driving experience and fulfilled
the requirements of section 4129 while continuing to ensure that
operation of CMVs by drivers with ITDM will achieve the requisite level
of safety required of all exemptions granted under 49 U.S.C.. 31136(e).
    Section 4129(d) also directed FMCSA to ensure that drivers of CMVs
with ITDM are not held to a higher standard than other drivers, with
the exception of limited operating, monitoring and medical requirements
that are deemed medically necessary.
    The FMCSA concluded that all of the operating, monitoring and
medical requirements set out in the September 3, 2003 notice, except as
modified, were in compliance with section 4129(d). Therefore, all of
the requirements set out in the September 3, 2003 notice, except as
modified by the notice in the Federal Register on November 8, 2005 (70
FR 67777), remain in effect.

IV. Submitting Comments

    You may submit your comments and material online or by fax, mail,
or hand delivery, but please use only one of these means. FMCSA
recommends that you include your name and a mailing address, an email
address, or a phone number in the body of your document so that FMCSA
can contact you if there are questions regarding your submission.
    To submit your comment online, go to http://www.regulations.gov and
in the search box insert the docket number FMCSA-2017-0035 and click
the search button. When the new screen appears, click on the blue
``Comment Now!'' button on the right hand side of the page. On the new
page, enter information required including the specific section of this
document to which each comment applies, and provide a reason for each
suggestion or recommendation. If you submit your comments by mail or
hand delivery, submit them in an unbound format, no larger than 8\1/2\
by 11 inches, suitable for copying and electronic filing. If you submit
comments by mail and would like to know that they reached the facility,
please enclose a stamped, self-addressed postcard or envelope.
    We will consider all comments and material received during the
comment period. FMCSA may issue a final determination at any time after
the close of the comment period.

V. Viewing Comments and Documents

    To view comments, as well as any documents mentioned in this
preamble, go to http://www.regulations.gov and in the search box insert
the docket number FMCSA-2017-0035 and click ``Search.'' Next, click
``Open Docket Folder'' and you will find all documents and comments
related to this notice.

    Issued on: May 26, 2017.
Larry W. Minor,
 Associate Administrator for Policy.
[FR Doc. 2017-11640 Filed 6-5-17; 8:45 am]
 BILLING CODE 4910-EX-P


[Federal Register: March 17, 2010 (Volume 75, Number 51)]
[Notices]
[Page 12770-12771]
[DOCID:fr17mr10-92]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID: FEMA-2009-0001]

Agency Information Collection Activities: Submission for OMB
Review; Comment Request, OMB No. 1660-NEW; Radiological Emergency
Preparedness Program Alert and Notification Phone Survey

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice; 30-day notice and request for comments; new information
collection; OMB No. 1660-NEW; FEMA Form 111, Radiological Emergency
Preparedness Program Alert and Notification Phone Survey.

-----------------------------------------------------------------------

SUMMARY: The Federal Emergency Management Agency (FEMA) has submitted
the information collection abstracted below to the Office of Management
and Budget for review and clearance in accordance with the requirements
of the Paperwork Reduction Act of 1995. The submission describes the
nature of the information collection, the categories of respondents,
the estimated burden (i.e., the time, effort and resources used by
respondents to respond) and cost, and the actual data collection
instruments FEMA will use.

DATES: Comments must be submitted on or before April 16, 2010.

ADDRESSES: Submit written comments on the proposed information
collection to the Office of Information and Regulatory Affairs, Office
of Management and Budget. Comments should be addressed to the Desk
Officer for the Department of Homeland Security, Federal Emergency
Management Agency, and sent via electronic mail to
<EMAIL_ADDRESS>or faxed to<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Requests for additional information or
copies of the information collection should be made to Director, Office
of Records Management, 1800 South Bell Street, Arlington, VA 20598-
3005, facsimile number<PHONE_NUMBER>, or e-mail address FEMA-
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

Collection of Information

    Title: Radiological Emergency Preparedness Program Alert and
Notification Phone Survey.
    Type of information collection: New information collection.
    OMB Number: OMB No. 1660-NEW.
    Form Titles and Numbers: FEMA Form 111, Radiological Emergency
Preparedness Program Alert and Notification Phone Survey.
    Abstract: Immediately following activation of a commercial nuclear
power plant's alert and notification system, FEMA will conduct a
telephone survey of a sample of residents within that plant's Emergency
Planning Zone.
    Affected Public: Individuals or households.
    Estimated Number of Respondents: 338.
    Frequency of Response: Once.
    Estimated Average Hour Burden per Respondent: .1667 burden hours.
    Estimated Total Annual Burden Hours: 56 burden hours.
    Estimated Cost: None.

    Dated: March 3, 2010.
Larry Gray,
Director, Office of Records Management, Office of Management, Federal
Emergency Management Agency, Department of Homeland Security.
[FR Doc. 2010-5851 Filed 3-16-10; 8:45 am]
BILLING CODE 9111-46-P